48 stories found
A review of Margaret Atwood's 'The Testaments' describes the novel as a dark and bloody sequel to 'The Handmaid’s Tale', continuing the story of June's daughter in Gilead.
Gilead Sciences announced its intention to acquire Tubulis, a company specializing in antibody-drug conjugates (ADCs), in a deal valued at $5 billion, expanding its oncology pipeline.
Investors are anticipating several key earnings reports from major companies, including PG&E Corporation, Procter & Gamble, CenterPoint Energy, and Gilead Sciences, that are set to be released after the market closes on Thursday.
Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.
Gilead Sciences has finalized its acquisition of autoimmune biotech company Ouro Medicines for up to $2 billion and will collaborate with Galapagos on the purchased assets.
“The Handmaid’s Tale” sequel “The Testaments,” based on a 2019 novel by Margaret Atwood, is expanding the Gilead universe.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) The Globe and Mail
Wall Street analysts have issued new ratings for biopharma companies, with Gilead receiving a 'Buy' recommendation, Amgen a 'Hold', and ORIC gaining a vote of confidence.
When you’re young and thinking of your life, it’s normal to envision fluffy white clouds, sunshine and rainbows. However, if you grew up in Gilead, your reality is much darker.
South Africa seeks local production of Gilead's HIV prevention drug Reuters
An international clinical trial, involving five Spanish hospitals, is testing a new single-pill daily treatment for HIV.
Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.
Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.
Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its presence in the biotechnology sector.
Hulu's upcoming 'Handmaid's Tale' spinoff, 'The Testaments,' will explore the theme of girlhood within the dystopian society of Gilead.
Gilead has reached an agreement to purchase the cancer biotechnology company Tubulis in a deal valued at $5 billion.
Galapagos has announced a partnership with Gilead on the drug Gamgertamig, a deal that unlocks $500 million in cash and sets sights on registrational trials by 2027.
Gilead Sciences is set to acquire biotech firm Ouro Medicines in a deal valued at $2.2 billion, marking its first TCE asset acquisition and aiming to boost its T cell therapy capabilities for autoimmune diseases.
Gilead Sciences has announced its acquisition of Ouro Medicines and a subsequent collaboration with Galapagos on the newly purchased assets, as reported by the Wall Street Journal.
The ladies of Gilead were in France, Saturday, for the world premiere of Hulu’s The Testaments.
A biotech company's $64 million exit reportedly missed a significant 77% one-day surge following a takeover deal by Gilead, indicating a potential miscalculation in the timing of the transaction.
After years of waiting, the saga of the totalitarian regime of Gilead gets its continuation.
In a dramatic departure from its predecessor, Hulu and MGM's coming-of-age next Margaret Atwood adaptation feels significantly lighter, even bordering on whimsical — before the cracks of resistance…
Hulu has released the trailer for “The Testaments,” the upcoming sequel series to “The Handmaid’s Tale.” “The Testaments” is set to premiere on April 8 with three episodes and is based on author…
A report highlights notable healthcare headlines for the week, focusing on developments related to pharmaceutical companies Viatris, Novo Nordisk, and Gilead Sciences.
Gilead Sciences' experimental HIV treatment has demonstrated low discontinuation rates in recent studies, indicating potential for improved patient adherence.
Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.
Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.
Barclays has adopted a neutral stance on Gilead Sciences, acknowledging its strategic refocus but maintaining a cautious outlook.
The spin-off series 'The Testaments,' based on 'The Handmaid's Tale,' is scheduled for release, continuing the narrative set in the totalitarian society of Gilead where women are deprived of their rights.
Galapagos NV announced it has signed an agreement with Gilead Sciences concerning assets related to Ouro Medicines. The details of the agreement were not immediately specified.
Galapagos NV and Gilead Sciences have entered into an agreement concerning the acquisition of Ouro Medicines, signaling a new development in the pharmaceutical sector.
US biopharmaceutical company Gilead Sciences has agreed to acquire Ouro Medicines for up to US$2.18 billion, gaining rights to an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences.
Gilead Sciences has announced plans to acquire Ouro Medicines and will subsequently collaborate with Galapagos on the assets obtained through the purchase.
This week, Elisabeth Moss and Lindsey McManus are celebrating the debut of Apple TV’s “Imperfect Women,” the first project the pair picked up after launching their Love & Squalor production banner…
Gilead Sciences, Inc. (GILD) is seeing its growth prospects bolstered by recent analyst upgrades, indicating positive sentiment in the market.
Os projetos selecionados abrangem as áreas do VIH, hepatites virais crónicas, cancro da mama e linfoma não hodgkin de células B. Ao todo, foram recebidas 47 candidaturas de diversas entidades.
Hulu reveals the first trailer for The Testaments.
The highly anticipated follow-up from Hulu, premiering April 8, stars Chase Infiniti as the daughter to Elisabeth Moss' heroine who is growing up in Gilead.
The company studied the pill in HIV patients whose virus was already suppressed, including those switching from complex multi-tablet regimens or from a guideline-recommended single-tablet treatment
Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.
Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion Reuters
Analysts are sharing their opinions and insights on Gilead Sciences (GILD) following its recent earnings report.